Abstract
### Safety and efficacy of galantamine in subjects with mild cognitive impairment Preventing the progression to Alzheimer disease and reducing cognitive symptoms are major treatment goals for all individuals with mild cognitive impairment (MCI) even though only a proportion of this heterogeneous population will eventually progress. The authors report on two 2-year, randomized, placebo-controlled trials that evaluate galantamine in MCI patients and find no significant influence on conversion rates to dementia and inconsistent benefits on other clinical outcomes. See p. 2024; Editorial, p. 2020 ### Longitudinal decline in autopsy-defined frontotemporal lobar degeneration The era of etiologically-specific …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
